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ABSTRACT
During virion maturation, HIV-1 capsid protein assembles into a conical core containing the viral ribonucleoprotein (vRNP)
complex, thought to be composed mainly of the viral RNA and nucleocapsid protein (NC). After infection, the viral RNA is re-
verse transcribed into double-stranded DNA, which is then incorporated into host chromosomes by integrase (IN) catalysis.
Certain IN mutations (class II) and antiviral drugs (allosteric IN inhibitors [ALLINIs]) adversely affect maturation, resulting in
virions that contain “eccentric condensates,” electron-dense aggregates located outside seemingly empty capsids. Here we dem-
onstrate that in addition to this mislocalization of electron density, a class II IN mutation and ALLINIs each increase the fraction
of virions with malformed capsids (from12% to53%). Eccentric condensates have a high NC content, as demonstrated by
“tomo-bubblegram” imaging, a novel labeling technique that exploits the susceptibility of NC to radiation damage. Tomo-
bubblegrams also localized NC inside wild-type cores and lining the spherical Gag shell in immature virions. We conclude that
eccentric condensates represent nonpackaged vRNPs and that either genetic or pharmacological inhibition of IN can impair
vRNP incorporation into mature cores. Supplying IN in trans as part of a Vpr-IN fusion protein partially restored the formation
of conical cores with internal electron density and the infectivity of a class II IN deletion mutant virus. Moreover, the ability of
ALLINIs to induce eccentric condensate formation required both IN and viral RNA. Based on these observations, we propose a
role for IN in initiating core morphogenesis and vRNP incorporation into the mature core during HIV-1 maturation.
IMPORTANCE
Maturation, a process essential for HIV-1 infectivity, involves core assembly, whereby the viral ribonucleoprotein (vRNP, com-
posed of vRNA and nucleocapsid protein [NC]) is packaged into a conical capsid. Allosteric integrase inhibitors (ALLINIs) affect
multiple viral processes. We have characterized ALLINIs and integrase mutants that have the same phenotype. First, by compar-
ing the effects of ALLINIs on several steps of the viral cycle, we show that inhibition of maturation accounts for compound po-
tency. Second, by using cryoelectron tomography, we find that ALLINIs impair conical capsid assembly. Third, by developing
tomo-bubblegram imaging, which specifically labels NC protein, we find that ALLINIs block vRNP packaging; instead, vRNPs
form “eccentric condensates” outside the core. Fourth, malformed cores, typical of integrase-deleted virus, are partially replaced
by conical cores when integrase is supplied in trans. Fifth, vRNA is necessary for ALLINI-induced eccentric condensate forma-
tion. These observations suggest that integrase is involved in capsid morphogenesis and vRNP packaging.
The formation of infectious HIV-1 particles starts with the coas-sembly of the Gag and Gag-Pol polyproteins into a spherical
shell, which buds from the cell to produce an immature virion (1).
Following budding, the viral protease (PR) is activated and cleaves
Gag and Gag-Pol into their component domains, of which the
capsid protein CA assembles into a conical capsid shell containing
the viral RNA (vRNA) genome, nucleocapsid protein NC, and
replication enzymes (we use the term “capsid” to denote the as-
sembled protein shell and “core” for the capsid plus whatever it
may contain). This transformation is known as HIV-1 matura-
tion. Drawing mainly on studies by cryoelectron tomography
(cryo-ET), a technique that allows three-dimensional (3D) imag-
ing of individual pleomorphic particles with good preservation of
native structure (e.g., see reference 2), a number of different mod-
els explaining how CA can assemble into conical cores have been
proposed (3–6). However, maturation—the process targeted not
only by protease inhibitors (PIs) (7) but also by “maturation in-
hibitors” that act by denying PR access to a key cleavage site (8,
9)—is incompletely understood.
Mutational studies of the viral enzyme integrase (IN) have
demonstrated that the effects of some amino acid substitutions,
the so-called class II IN mutations, include defects in particle as-
sembly and reverse transcription (compared to class I IN muta-
tions, which affect only integration) (reviewed in reference 10).
Class II IN mutant viruses provided an initial clue for a role of IN
in the late stages of replication, including maturation. More re-
cently, a group of investigational compounds, 2-(quinolin-3-yl)
acetic acid derivatives, which we refer to as allosteric integrase
inhibitors (ALLINIs) (11) but which are also called NCINIs for
noncatalytic IN inhibitors (12), LEDGINs for lens epithelium-
derived growth factor (LEDGF)/p75-IN inhibitors (13), INLAIs
for IN-LEDGF/p75 allosteric inhibitors (14), and MINIs for mul-
timeric IN inhibitors (15), were found to inhibit HIV-1 infection
(13, 16). ALLINIs engage the interface that is formed by two mol-
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ecules of the IN catalytic core domain at the binding pocket for the
cellular integration cofactor LEDGF/p75 (11, 13–15, 17–19),
which itself guides viral DNA integration to active genes (reviewed
in reference 20). Inhibition of the LEDGF/p75-IN interaction was
initially thought to underlie the mode of ALLINI action (13).
However, the compounds were since discovered to affect the late
stage of HIV-1 replication in a manner that is independent of
LEDGF/p75 expression (12, 15, 18, 21, 22). The compounds are
also active during the early stage of HIV-1 replication, but much
higher concentrations are required to achieve potencies similar to
those when virus producer cells are treated (12, 14, 15, 17, 18, 21,
22). Akin to several class II IN mutant viruses, particles produced
in the presence of ALLINIs are reportedly defective for multiple
steps of HIV-1 replication, namely, maturation (12, 15, 18, 21),
reverse transcription (12, 15, 18, 21), nuclear import of the viral
DNA (21), and integration (12–15, 18, 19, 21). The ability of
ALLINIs to induce higher-order IN oligomerization during virus
production underlies their antiviral activity (11, 12, 14, 15, 17–19,
21, 23, 24).
Transmission electron microscopy of thin sections of plastic
embeddings (referred to here as TEM) of HIV-1 particles gener-
ated in the presence of ALLINIs revealed an apparent uncoupling
of the incorporation of the viral ribonucleoprotein (vRNP) com-
plex, assumed to be composed primarily of vRNA and NC, from
assembly of the capsid (12, 15, 18, 21). Instead of a normal elec-
tron-dense core, a relatively electron-translucent core was ob-
served, accompanied by a roughly spherical electron-dense fea-
ture situated between the viral envelope. We refer to this feature as
an “eccentric condensate.” It follows that ALLINIs can be useful
probes to help understand how IN contributes to maturation, in a
similar way that maturation inhibitors (which prevent the scission
of the CA-SP1 junction within Gag, the final proteolytic cleavage
that leads to the generation of a mature core [25, 26]), or muta-
tions that prevent the cleavage of the Pol polyprotein (27, 28),
have provided structural insights.
In this study, we first analyzed the relationships between core
formation, reverse transcription, and infectivity of ALLINI-
treated particles and conclude from dose-response curves that in-
hibition of particle maturation is the process that underlies the
potencies of two representative ALLINI compounds. Using cryo-
ET, we found that, in addition to affecting vRNP incorporation
into the mature core, ALLINIs reduced by a factor of approxi-
mately five the efficiency with which conical cores are formed. To
demonstrate that the eccentric condensate is indeed composed of
NC and RNA, we applied tomo-bubblegram imaging, a novel
technique that takes advantage of the acute sensitivity of NC pro-
tein to electron irradiation that is expressed in the generation of
bubbles as radiation damage products. The same approach con-
firmed that NC, and by inference the vRNP, is present inside wild-
type cores, predominantly at the wide end, and that NC lines the
inner part of the thick-walled Gag shell in immature virions. Using
Vpr-IN to functionally transcomplement particles that lack IN
(IN), we also show that IN promotes conical core formation and
HIV-1 infectivity in parallel. Furthermore, we implicate vRNA as
a necessary component for ALLINI action during virus produc-
tion. Together, these results imply that IN has a direct role in
nucleating the assembly of conical cores and the incorporation of
the vRNP into the mature core and that ALLINI treatment effec-
tively subverts this role(s) of IN during HIV-1 particle matura-
tion.
MATERIALS AND METHODS
Plasmids and antivirals. HIV-1NL4-3 carrying wild-type (WT) IN was
expressed from pNL43/Xmal (29), whereas the V165A IN mutant was
expressed from pNL43/XmaI.V165A (30). Single-round derivatives HIV-
Luc and HIV-Luc.IN were expressed from pNLX.Luc.R (31) and
pNLX.Luc.R.IN (18), respectively. The D25A mutation in PR was in-
troduced into pNL43/XmaI using PCR-directed mutagenesis. Gag/-mi-
nus virus-like particles (VLPs) were expressed from pRR359 (32) (also
known as pCMV55M1-10 [32, 33]) whereas Gag-LeuZip was expressed
from pRR546 (32). The HIV-1-based pHP-dI-N/A packaging plasmid
(34) was cotransfected with pHI-Luc transfer vector (35) or pGL3-Basic
control plasmid (Promega). Vpr fused to the IN protein from HIV-1SG3
(WT or H171T mutant) was expressed from pRL2PVpr-IN (18, 36),
whereas the vesicular stomatitis virus G (VSV-G) glycoprotein was ex-
pressed using pCG-VSV-G (31).
ALLINIs BI-D and BIB-2 were synthesized as described previously (23,
37). Efavirenz (EFV) was obtained from the National Institutes of Health
AIDS Research and Reference Reagent Program (NIH ARRRP).
Cells, viruses, and antiviral assays. Transformed human embryonic
kidney 293T (HEK293T) cells (American Type Tissue Collection item
number CRL-3216) were grown in Dulbecco’s modified Eagle medium,
while human SupT1 T cells (NIH ARRRP item number 100) were main-
tained in RPMI 1640 medium, both supplemented to contain 10% (vol/
vol) fetal bovine serum, 100 IU/ml penicillin, and 100 g/ml streptomy-
cin. HIV-Luc was produced by cotransfecting HEK293T cells (8  105)
with 3.5 g pNLX.Luc.R and 0.35 g pCG-VSV-G using PolyJet trans-
fection reagent (SignaGen Laboratories). HIV-1NLX.Luc.R.IN was
transcomplemented with Vpr-IN by cotransfecting HEK293T cells (3 
106) with 4.5 g pNLX.Luc.R.IN, 1.25 g pRL2P-Vpr-IN containing
WT or H171T mutant IN, and 0.5 g pCG-VSV-G. Dimethyl sulfoxide
(DMSO) or ALLINIs were added with fresh medium at 17 to 20 h
posttransfection, and cell supernatants were collected 24 h later. The cell-
free virus concentration, typically 500 to 1,000 ng/ml, was determined
using a commercial p24 ELISA kit (Advanced Biosciences Laboratories).
For Vpr-IN complementation experiments, SupT1 cells were infected in
quadruplicate with 5 ng/ml p24. Luciferase values, expressed in relative
light units, were determined 48 h postinfection.
DNA analysis and quantitative PCR. SupT1 cells (2 106) infected
with DNase-treated (1 h at 37°C) HIV-Luc (50 ng p24/ml) for 2 h were
washed and split into two samples. DNA was isolated from one set of
samples 5 h later by use of a DNeasy blood and tissue kit (Qiagen). The
other set of samples was seeded in quadruplicate in 96-well plates, and
luciferase activity was determined 48 h from the start of infection.
Duplicate PCR mixtures containing 50 ng DNA, 0.2 M primers
(AE2963/AE4422), 0.1 M probe (AE2965), and 1 QuantiText Probe
PCR master mix were incubated at 50°C for 2 min and 95°C for 15 min,
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followed by 40 cycles of 94°C for 15 s, 59°C for 30 s, and 72°C for 30 s (38).
Standards were prepared by endpoint dilution of pNLX.Luc.R into
DNA from uninfected cells. To account for potential residual plasmid
carryover from transfection, parallel infections were performed in the
presence of 10 M EFV, and the values obtained from these PCR assays
were subtracted from the values from the experimental samples.
RNA isolation and analysis. Total RNA was extracted from concen-
trated virus preparations after a 30-min incubation with 0.05 g/ml pro-
teinase K (Life Technologies) and 0.4% sodium dodecyl sulfate at 56°C.
Following phenol-chloroform extraction, RNA was precipitated using
isopropanol and GenElute-LPA (Sigma-Aldrich) as the carrier. The RNA
concentration was determined by the Ribogreen (Invitrogen) assay, which
was completed according to the manufacturer’s instructions. PCRs to
determine vRNA copy number per nanogram of total RNA were com-
pleted as previously described (18), utilizing 2 l of purified RNA and
primer sets AE2963/AE2964 for Fig. 9 samples (excluding HIV-Luc) and
AE2961/AE4422 for Fig. 6 samples and HIV-Luc.
TEM. Viruses produced from transfected HEK293T cells were pelleted
at 30,000 rpm at 4°C for 1.5 h with a Beckman SW41 rotor. Pelleted virus
was resuspended in a small volume of phosphate-buffered saline. An
equal volume of 4% EM-grade paraformaldehyde (Electron Microscopy
Sciences) was added, and samples were incubated at 4°C before being
embedded in Epon resin. Thin (75- to 100-nm) sections were applied to
200-mesh carbon-coated copper grids, stained with 0.2% lead citrate, and
observed using either a Tecnai-12 (FEI) or JEOL 1200EX microscope
equipped with a Gatan or AMT 2k charge-coupled device (CCD) camera,
respectively. Images were captured at 37,500 magnification and were
visually scanned to count 100 viral particles per preparation.
Cryo-ET. HIV-1 carrying the V165A mutation, WT virions produced
with the indicated concentration of ALLINIs or DMSO control, PR-de-
fective (PR) virions, Gag/-minus VLPs, and Gag-LeuZip VLPs were
pelleted as described above and were imaged by cryo-ET as described
previously (39). In brief, purified fixed virus was mixed (2:1) with a
suspension of colloidal gold particles (Electron Microscopy Sciences), ap-
plied to Quantifoil R2/2 holey carbon grids (Structure Probe, Inc.), and
plunge-frozen in a Vitrobot instrument (FEI). For data acquisition, grids
were transferred to a cryo-holder (type 626; Gatan), and single-axis tilt
series were recorded on a Tecnai-12 electron microscope equipped with
an energy filter (GIF 2002; Gatan) operated at 120 keV in zero-loss mode
with an energy slit width of 20 eV. Images were acquired on a 2,048- by
2,048-pixel CCD camera (Gatan) using SerialEM (40). Tilt-series projec-
tions were acquired at 2° intervals from 66° to 66°, at 38,500
magnification (0.78-nm/pixel) and a defocus of 4 m. The electron
dose per projection was1.1 e/Å2, giving a total cumulative dose of75
e/Å2. Tilt series were reconstructed using the Bsoft package (41), and
virions were extracted as subtomograms and denoised by 20 iterations of
anisotropic nonlinear diffusion (42).
Bubblegram and tomo-bubblegram imaging. Dose series of HIV-1
particles were acquired either on a CM200-FEG TEM (FEI), operating at
120 keV with doses of 17 e/Å2 per exposure, or in a Tecnai-12 TEM
operating at 120 keV at5 e/Å2 per exposure. All images were collected
on 2,048- by 2,048-pixel CCD cameras. Filled cores and eccentric aggre-
gates bubbled at average doses of 165 40 e/Å2 (n	 109).
The procedure used to collect and analyze data for tomo-bubblegram
imaging is described in Results. The imaging was performed on virions
located over holes (and not near their edges) in the Quantifoil grids. The
distances from the bubble centers to the center of the viral envelope were
measured using Bsoft programs. Briefly, after extraction and centering of
a virion, its radius was estimated as follows. First, to reduce noise and to
suppress “missing wedge” effects (43), particles were spherically symme-
trized (for ease of implementation, we applied icosahedral symmetry,
which is not present in HIV-1 virions but gave a close approximation to
spherical symmetry and could be applied with the software available).
Then the radius was estimated from a density profile of the symmetrized
particle. The bubble centers were then selected manually in the tomo-
bubblegram, using the BshowX utility, and the distances of the bubbles
from the envelope were calculated by subtracting the distance from the
center of the bubble to the center of the particle from the particle radius at
the middle of the envelope. Isosurface rendering of viral particles was
done in Chimera (44).
Bacterially expressed recombinant NC was purified as previously de-
scribed (45) and lyophilized after the addition of one equivalent Zn2
 per
zinc finger. NC was then resuspended in buffer (25 mM HEPES, 30 mM
NaCl, 1 mM MgCl2, 3 mM dithiothreitol [DTT], and 10% of glycerol at
pH 7.5) at a concentration of 10 M, aliquoted, and immediately frozen
and stored at80°C. For cryo-EM, thawed aliquots (25 l) were centri-
fuged at maximum speed for 5 min in a tabletop centrifuge and the top 20
l was discarded. The remaining 5 l was applied to a 400-mesh copper
grid covered with a thin carbon film supported by a thick lacy carbon film,
washed with buffer (25 mM HEPES, 10 mM NaCl, 1 mM MgCl2, pH 7.5)
to remove the glycerol, and plunge-frozen and imaged in a Tecnai-12 EM
as described above.
RESULTS
Inhibition of virion maturation underlies ALLINI potency.
ALLINIs have been reported to inhibit multiple aspects of HIV-1
replication, including virion maturation, reverse transcription,
nuclear import, and integration (see the introduction), suggesting
that it may be the combination of multiple inhibitory processes
that underlies ALLINI potency. An alternative scenario is that in-
hibition may be due to a single dominant or bottleneck step,
which in this case would be particle maturation, as it is the first
step inhibited from the perspective of the virus producer cell. To
investigate this possibility, we compiled dose-response curves
measuring the first two steps affected by ALLINIs—maturation
and reverse transcription—and compared them to overall antivi-
ral activity as assessed by the expression of the luciferase reporter
gene in cells infected with drug-treated HIV-Luc particles. If mat-
uration is a bottleneck step, we anticipated that its inhibition
would equate with antiviral potency. If inhibition of multiple steps
is involved, then the maturation and reverse transcription inhib-
itory curves would individually be less potent than overall antivi-
ral activity.
HIV-Luc was produced in the presence of two representative
ALLINI compounds, BI-D, with a 50% effective concentration
(EC50) for inhibition of HIV-1 infection of 89 nM, and BIB-2 (also
known as ALLINI-2), with an EC50 of 630 nM (23, 37) (Fig. 1), at
various EC50 doses (1, 2, 4, and 8). TEM analysis of virus
made in the presence of the solvent control DMSO revealed that
87% 2% (mean SD) of these particles harbored mature cores
with internal density. This value decreased by 50% when virus
was produced with unit EC50s of BI-D or BIB-2, with accompany-
FIG 1 Chemical structures of BI-D and BIB-2.
Integrase Inhibitors Act on HIV-1 Core Assembly
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ing increases in particles containing eccentric condensates (Fig.
2A). Higher doses of each compound further reduced the fraction
of mature cores and increased the fraction of eccentric conden-
sate-containing particles. The reverse transcription activity and
infectivity (luciferase activity) of the particles were measured in
SupT1 cells infected with equal amounts of virus, as quantitated
by their CA/p24 content. By comparing the results of Fig. 2A and
B, we determined that the effect of drug treatment on reverse
transcription activity closely paralleled the inhibition of mature
core formation (Pearson correlation coefficient [r2] 	 0.998 for
the two sets of dose-response curves; P  0.001). Inhibition of
reverse transcription, moreover, paralleled overall antiviral activ-
ity (Fig. 2C; r2	 0.903 for these two data sets; P 0.001).
ALLINI treatment affects conical core assembly in addition
to vRNP incorporation into the mature core. Having determined
that the antiviral activity of two independently tested, representa-
tive ALLINIs is due to their inhibition of particle maturation, we
performed cryo-ET to further probe the antiviral phenotype. Vi-
rions produced with fully inhibitory ALLINI concentrations (10
EC50 for BIB-2; 10 to 100EC50 for BI-D) (Fig. 2C) were classified
according to core morphology (conical, e.g., see Fig. 3A and B;
nonconical, e.g., see Fig. 3C and D; or no core, e.g., see Fig. 4A),
and the presence (Fig. 3B and D and Fig. 4B) or absence (Fig. 3A
and C and Fig. 4A) of an eccentric condensate. The eccentric con-
densate was previously observed by TEM as a compact, darkly
staining body common to class II IN mutant viruses (12, 18, 46,
47) and ALLINI-treated virions (12, 15, 18). We used cryo-ET to
extend these observations (Fig. 3B and D). Their compactness and
density distinguish condensates from the other material that typ-
ically occupies the space between the core and the viral envelope,
which we take to be mostly nonpolymerized CA (48, 49) and host
cell proteins (50). In BI-D-treated particles, the eccentric conden-
sates have ellipsoidal shapes with major and minor axes of 58 12
nm and 37 12 nm (n	 93), respectively; those present in par-
ticles treated with BIB-2 or untreated V165A mutant particles,
which was utilized as a class II IN mutant control (18), were sim-
ilar in size. The incidence of these morphological classes is sum-
marized in Fig. 3E. Eccentric condensates are relatively rare
(12%) in wild-type (WT) virions but present in 75% of par-
ticles treated with BI-D or BIB-2 or with the V165A IN mutant.
We observed no virions with more than one eccentric condensate.
As in earlier studies by cryo-ET (e.g., see references 3, 4, and
25), most WT virions (77%) were found to have closed conical
cores with internal density (Fig. 3A), noting that the tomograms
would not detect small holes if present (51). Most of the eccentric
condensate-containing virions from BI-D or BIB-2 treatment or
the V165A IN mutant also have cores (Fig. 3E), but there are two
striking differences between these cores and WT cores. First, they
have a much higher incidence of nonconical cores than the WT
(the ratios of nonconical to conical cores were 1.8:1 for BI-D, 0.9:1
for BIB-2, and 1.6:1 for V165A, compared to 1:7.2 for WT). Thus,
there is marked impairment of capsid morphogenesis. Second,
V165A mutant, BI-D, and BIB-2 conical cores are relatively
empty, as exemplified by comparing Fig. 3A and B. With WT
FIG 2 Inhibition of virion maturation underlies ALLINI potency. (A) (Left) Quantitation of core morphotype frequencies (average SD for two independent
experiments) for sets of 100 counted HIV-Luc particles; (right) representative TEM images of mature, eccentric, and immature virions produced in these
experiments. (B) Quantitation of late reverse transcription (LRT) product formation from infections initiated with samples shown in panel A. (C) Antiviral
activity as assessed by bulk luciferase output. Error bars in panels B and C represent the variations obtained from three independent experiments.
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cores, internal material is generally taken to consist mainly of the
vRNP, although this assignment has not been formally demon-
strated and is addressed further below. While V165A mutant,
BI-D, and BIB-2 cores have less internal content than the WT
ones, they tend to have some internal material (e.g., see Fig. 3D).
With this caveat, we estimate that50% of them have little or no
content compared to 3% for the WT virions. These data suggest
that V165A mutant, BI-D, and BIB-2 virions are deficient in cap-
sid morphogenesis as well as incorporation of the vRNP into the
mature core.
Bubblegrams detect radiation-sensitive material in filled
cores and eccentric condensates. It is plausible that eccentric
condensates represent NC-vRNA complexes that failed to be in-
corporated into the mature core. We obtained supporting evi-
dence for this hypothesis by means of a labeling technique called
bubblegram imaging (52, 53). Vitrified samples imaged in an elec-
tron microscope undergo progressive damage by electron irradi-
FIG 3 Classification of HIV-1 particles observed by cryo-ET. (A to D) Tomographic central slices of representative HIV-1 virions classified according to core
morphology (conical or nonconical) and the presence or absence of an eccentric condensate (white arrows). Eccentric condensates appear denser than the
material lying between the core and the envelope in particles that lack an eccentric condensate. The cores of virions that have an eccentric condensate are relatively
empty (e.g., panel B). Bar, 50 nm. (E) Percentages of HIV-1 virions classified according to their core morphology (conical, nonconical, or no core) and presence
or absence of an eccentric condensate. The majority species for each sample is indicated by values in bold. According to the chi-square test, significant differences
with P values of0.00001 were found for comparisons between WT and BIB-2 and between WT and the V165A mutant. The difference between WT and BI-D
had a P value of 0.013, whereas the differences between the V165A mutant and BI-D or BIB-II were not significant, with P values of0.26. The chi-square test
was used to test for equal distribution of compartmentalized data but should not be used if more of 20% of the bins contain fewer than 5 counts. Therefore,
immature virions were not taken into account and virions with no cores were considered a single category, independent of the presence or absence of an eccentric
condensate.
FIG 4 Examples of relatively rare morphotypes observed in populations of
WT virions. (A) Central tomographic slice of a WT particle without a core or
eccentric condensate; (B) central tomographic slice (left) and corresponding
tomo-bubblegram slice (right) of a WT particle containing an eccentric con-
densate (marked with an arrow in the left panel). The core is a conical one
sampled in an oblique section. While the core is not entirely empty, it lacks
sufficient internal density to suggest that it contains a vRNP. This interpreta-
tion is confirmed by the bubbling being confined to the eccentric condensate.
Bar, 50 nm.
Integrase Inhibitors Act on HIV-1 Core Assembly
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ation. This damage is initially expressed as a “smearing” of the
macromolecular density, and for this reason the electron dose is
kept as low as possible during imaging (54). When proteinaceous
specimens are subjected to relatively high levels of electron irradi-
ation in cryo-EM, perhaps 10-fold higher than the dose used in a
typical imaging experiment, bubbles of hydrogen gas are gener-
ated (55, 56) which are readily visible due to their low density.
Different proteins have different bubbling thresholds (N. Cheng,
FIG 5 Tomo-bubblegrams of HIV-1 particles. (A to X) Each pair of panels shows a central section from an initial tomogram (left) and the corresponding section from
the tomo-bubblegram (right). The types of virions analyzed are indicated on the left of each block. BIB-2 (10) and BI-D (10 EC50 for panels G, I, and L; 100 EC50
for panels H, J, and K) were used at full inhibitory concentrations. Particles with conical cores are framed in red, and those with nonconical cores are framed in blue;
particles lacking eccentric condensates are framed with continuous lines, and particles that have eccentric condensates are framed with dashed lines. Bar, 50 nm. Full
tomograms of the virions in panels B (Movie S1), I (Movie S2), R (Movie S3), and X (Movie S4) are shown in the supplemental material.
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Weimin Wu, Anastasia Aksyuk, J. Fontana, and A. C. Steven, un-
published observations). Moreover, proteins embedded in DNA
bubble relatively early because the densely packed DNA impedes
the diffusion of radiation products from their sites of origin, ac-
celerating their buildup to a critical concentration for bubbling.
Hypothesizing that compact NC-vRNA condensates may have
distinctive bubbling behavior, we subjected HIV-1 virions to
bubblegram imaging. In dose-series micrographs (not shown),
small bubbles first appeared after a cumulative dose of 160 to 200
e/Å2 and grew in size and number with subsequent exposures.
The bubbles coprojected with filled cores and eccentric conden-
sates, and the two structures appeared to have the same bubbling
threshold, although in some micrographs the boundaries of these
structures were difficult to discern. However, we could not rule
out that the bubbles may not be inside these structures but coin-
cidentally lie along the same line-of-sight.
Aiming to eliminate the ambiguity of coprojection, we ex-
tended the bubblegram method to 3D imaging by electron tomog-
raphy. We call this method tomo-bubblegram imaging. First, a
regular tilt series is collected from an area of interest and a tomo-
gram is calculated. This involves a total dose of75 e/Å2, which
is below the bubbling threshold for HIV-1. Second, an untilted
dose series is recorded, stopping after the first small bubbles begin
to develop (another 70 e/Å2). Third, after waiting 2 h to
allow radiation products to dissipate, a second tilt series is re-
corded (70 e/Å2) during which larger bubbles appear in the
“primed” specimen. These bubbles are visualized in the corre-
sponding tomogram, the tomo-bubblegram. Finally, a compari-
son of the first tomogram (the “before” state with the virions in a
close-to-native state) and the second one (the “after” state) allows
the sites in which the bubbles nucleated to be mapped in three
dimensions. As illustrated in Fig. 5, Movies S1 to S4 in the supple-
mental material, and Table 1, the bubbles specifically label the core
interiors in WT virions, predominantly toward the wide end of the
core. They also label the eccentric condensates of V165A mutant
and BI-D or BIB-2 virions. Of note, bubbles were never seen only
inside cores (i.e., outside the condensates) of V165A mutant or
BI-D or BIB-2 virions that also contained eccentric condensates:
in these particles, bubbles were observed either only in the con-
densate (80% of the condensate-containing particles) or in both
the condensate and the core (20%). In summary, we found that
the WT conical core contents and eccentric condensates are more
prone to bubbling than the other components of the virion (CA
protein, MA protein, envelope glycoprotein) and that they are
indistinguishable in this respect. In turn, this correlation strongly
supports the idea that they are chemically the same and are indeed
NC-vRNA complexes.
Bubbles label NC-RNA in immature virions. To further in-
vestigate which component of HIV-1 virions is bubbling, we ex-
amined immature (PR-defective [PR]) virions in which, in the
absence of proteolysis, the Gag and Gag-Pol domains are radially
ordered, with MA in contact with the viral membrane and CA and
NC/vRNA arranged in successive concentric layers. PR virions
(HIV-1NL4-3 with the D25A inactivating mutation in the PR active
site) exhibited a similar bubbling threshold as WT virions, al-
though the bubbles appeared in a different location, i.e., within the
Gag shell (Fig. 6Ai and ii; see also Movie S5 in the supplemental
material). Radially, these bubbles are centered at 15 nm (aver-
age, 15 5 nm; n	 333) in from the middle of the viral envelope,
a position that corresponds to the interface between the CA and
NC/vRNA layers (Fig. 7). In the other two dimensions of the Gag
lattice, we did not find a preference for bubbling in any particular
location.
Next, immature virions in which vRNA and NC were respec-
tively eliminated from Gag virus-like particles (VLPs) were ana-
lyzed to test for the relative contributions of these two compo-
nents to bubbling phenomena. A VLP construct that lacked the
vRNA  region (33) reduced the packaging of vRNA relative to
total virion RNA by20,000-fold (Fig. 6C). Gag/-minus parti-
cles bubbled in the same locations as immature (PR) virions,
thus showing that vRNA is not needed for bubbling (Fig. 6Aiii and
iv; see also Movie S6 in the supplemental material). We do, how-
ever, note that the bubbling appeared to be slightly reduced with
this construct (16  10 bubbles/virion in Gag/-minus particles
versus 27  15 bubbles/virion in PR particles [Table 2]; the
differences are significant at a P of 0.01 according to the two-
tailed Student t test). The difference, such as it is, might arise from
the2.5-fold reduction in overall RNA content in Gag/-minus
particles, as the RNA may impede the dispersal of hydrogen gas
generated from NC. To eliminate NC but nevertheless retain
structurally similar particles, we used a construct, termed Gag-
LeuZip, in which the NC domain of Gag was replaced by a leucine
TABLE 1 Tomo-bubblegram labeling of HIV-1 virions
Sample type
% of virions with bubblesa
Conical core, no condensate Nonconical core, no condensate
Condensate with core (conical or
nonconical)
Inside
core
Outside
core Both
Inside
core
Outside
core Both
Outside
condensate
Inside
condensate Both
WT (n	 78) 55 0 19 1 3 3 4 4 9
BI-D (n	 72) 7 0 7 1 1 6 0 56 21
BIB-2 (n	 64) 8 0 0 0 3 0 0 77 12
V165A mutant (n	 88) 3 0 2 6 0 2 0 67 18
a The data are shown as percentages of virions with bubbles either inside the core, outside the core, or both. The majority species for each sample type is indicated by bold values.
Few particles have no bubbles (3% of the virions observed), and they were not included in this analysis. According to the chi-square test, highly significant differences with P
values of0.00001 were found for comparisons between WT and BIB-2 samples and between WT and V165A mutant samples. The comparison between WT and BI-D samples
yielded a P value of 0.009, whereas the differences between the V165A mutant and BI-D or BIB-II samples were not significant, with P values of0.25. To make possible the
application of the chi-square test, only four categories were considered: virions with conical or nonconical core without eccentric condensate that were labeled inside the core or
inside and outside the core, and virions with condensate and core (conical or nonconical) that were labeled inside the condensate (i.e., eighth column) or inside and outside the
condensate (i.e., ninth column).
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FIG 6 Tomo-bubblegrams of immature HIV-1 particles. (Ai to Avi) Central tomographic sections (left) and corresponding tomo-bubblegram sections (right).
Full tomograms of the virions in panels Aii (Movie S5), Aiii (Movie S6), and Avi (Movie S7) are shown in movies in the supplemental material. The diagrams on
the left side of the figure illustrate the composition of each sample. PR particles contain the Gag and Gag-Pol polyproteins that include NC and incorporate
vRNA. The virions are immature due to the inactivating D25A mutation in the PR active site. Gag/-minus particles are also immature, and additionally their
RNA lacks the region and therefore vRNA is not incorporated into particles. The Gag-LeuZip particles replace NC with a leucine zipper; these particles lack NC
and vRNA. Bar, 50 nm. (B) Total virion RNA from the particles described for panel A. RNA concentration was normalized to the Gag signal obtained from
anti-p24 Western blots of multiple input volumes. Shown are the averages (SD) of total RNA (in nanograms) standardized by Gag signal for four independent
experiments, reported as a percentage of PR. (C) RNA from panel B was utilized to determine the copy number of vRNA. Values, reported as a percentage of
PR, are the averages (SD) for four independent experiments.
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zipper (32) but in which Gag otherwise retains its immature con-
formation (57). The Gag-LeuZip VLPs yielded almost no bubbles
(Fig. 6Av and vi; see also Movie S7) (0.3 bubbles/virion versus 16
bubbles/Gag/-minus VLP at the same electron doses), and
94% of these particles had 0 or 1 bubble (versus 100% of the
control particles that each had two or more bubbles) (Table 2).
The relative levels of total RNA and vRNA in Gag-LeuZip VLPs
were similar to those in Gag/-minus VLPs (Fig. 6B and C),
though we do note that an earlier study failed to detect tangible
RNA levels in Gag-LeuZip VLPs (32). Nevertheless, we conclude
that apart from a very low background of bubbles from other
sources (as illustrated in Fig. 6Av and vi), NC protein is the bub-
bling component.
Purified NC exhibits bubbling behavior similar to that ob-
served in mature and immature virions. Identification of NC
protein as the component responsible for bubbling in both mature
WT and IN mutant or ALLINI-treated virions and in immature
virions led to the prediction that NC protein should also bubble
provided that it is suitably concentrated. To test this hypothesis,
we examined aggregates of purified NC. Aggregates were similar
in diameter to eccentric condensates (average, 51  20 nm [n 	
69] versus 48  9 nm [n 	 93], respectively) and were found to
FIG 7 Locations of bubbles in PR virions. (A) Cryo-ET central slice of an immature PR particle. (B and C) Tomo-bubblegram section corresponding to panel
A. In panel C, bubbles are marked with red circles. (D) Surface rendering of a cutaway slice of the particle shown in panels A to C. Most of the bubbles (white)
are located between the CA layer (green) and the NC-vRNA layer (yellow). The viral envelope is in cyan, and the internal contents are in red. Bar, 50 nm. (E)
Radial density profile of subtomogram averaged Gag from immature virions (from reference 25). (F) Histogram of the distance from the center of the bubbles
to the center of the viral envelope (membrane
MA).
TABLE 2 Bubbles in three kinds of PR HIV-1 particles
Particle type
No. of
tomograms
Total avg dose
(e/Å2)
No. of
virions
No. of
bubbles/viriona
% of virions with 2 or
more bubbles
% of virions with 1 or
no bubbles
PR 3 215 65 27 15 100 0
Gag/-minus 4 221 53 16 10 100 0
Gag-LeuZip 4 228 53 0.3 0.6 6 94
a For PR and Gag/-minus VLPs, the bubbles from 29 and 31 virions, respectively, were counted. For the Gag-LeuZip, bubbles from all particles imaged were counted.
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have a bubbling threshold similar to that of eccentric condensates
(average, 154 57 e/Å2 [n	 69] versus 165 42 e/Å2 [n	 69],
respectively). Their bubbling threshold was somewhat dependent
on size, with larger aggregates bubbling earlier than smaller ones
(Fig. 8). This is consistent with the greater abundance of NC in
larger aggregates providing a richer source of hydrogen gas as a
radiation product. Strikingly, bubbling started in the middle of
these aggregates and then spread outwards, consistent with the
outer layers of molecules impeding the outward diffusion of the
gas. Taken together, these observations provide strong evidence
that the bubbling component in HIV-1 virions is NC protein and
therefore confirm that ALLINI treatment affects incorporation of
the vRNP into the core.
ALLINI-induced eccentric condensate formation requires
vRNA. To address whether ALLINI-mediated impairment of
vRNP incorporation into the mature core is dependent upon the
species of RNA within the virus, we cotransfected pHI-Luc, which
expresses a minimal HIV-1 transfer vector that harbors45% of
the full-length vRNA genome, with pHP-dI-N/A, which expresses
the Gag and Pol proteins required to package HI-Luc vRNA in
trans. As a transfection control for pHI-Luc, we utilized the pro-
moterless pGL3-basic (GL3-B) construct that carries the luciferase
FIG 8 Bubblegram imaging of purified NC protein. (A to E) Cryo-EM dose series of five NC aggregates of different sizes. The images in which bubbles first appear
are labeled with a white asterisk in each case (although NC is formally soluble, small aggregates of suitable size were consistently found on EM grids). Bar, 50 nm.
(F) Plot of the diameters of NC aggregates versus the cumulative electron dose at which they started bubbling. Points corresponding to the aggregates from panels
A to E are shown in red. While the data exhibit some stochastic variability in bubbling threshold, there is a clear trend toward larger aggregates requiring less
electron radiation to initiate bubbling. A linear fit is shown for reference (red line).
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gene but lacks HIV-1-related sequences and the capacity to ex-
press RNA. Total RNA levels of pelleted virions nevertheless did
not vary significantly between those made in the presence of pHI-
Luc or GL3-B, although, as expected, the HIV-1 genome was se-
lectively incorporated into HI-Luc particles (Fig. 9A and B). We
also note that HI-Luc total and vRNA levels were similar to those
of the HIV-Luc virions characterized in Fig. 2.
TEM revealed that30% of HI-Luc viruses harbored WT-like
conical cores, 22% harbored cores as well as eccentric aggre-
gates,25% had a previously unseen morphology in which dual
electron density (dual ED) appeared both inside and outside the
core, 15% had empty cores, and 15% contained immature-
like spherical shells (Fig. 9C). The baseline phenotype of virions
made in the presence of GL3-B did not differ dramatically from
that of virions that harbored HI-Luc vRNA (Fig. 9C). As expected,
BI-D treatment increased the frequency of HI-Luc virions with
eccentric aggregates (60%), with accompanying decreases in
mature (5%) and dual ED (1%) cores. In contrast, the fraction
of virions with eccentric aggregates did not significantly change
when sham virus made in the presence of GL3-B was treated with
BI-D (Fig. 9C).
Partial recovery of WT core formation by IN in trans. TEM
classification of IN virions revealed that the majority (61%)
contained eccentric condensates while 9% harbored WT-like
conical cores and30% were immature (18). To assess the role of
IN in HIV-1 maturation and the impact of ALLINI treatment on
this role,IN virions were functionally transcomplemented by IN
fused to the viral accessory protein Vpr. INH171T, which confers
44-fold resistance to BI-D (58), was utilized as a control. Al-
though class II IN mutations such as IN can impede CA/p24
release in a cell type-dependent manner (31, 59), the IN virus
used here yielded supernatant p24 values similar to those of the
WT control virus (18). Vpr-IN boosted the infectivity of the
highly defective IN virions100-fold, to a level equal to5 to
10% of the infectivity of the parental HIV-Luc virus (Fig. 10A). As
expected (18), a 10EC50 dose of BI-D abolished the infectivity of
FIG 9 Viral RNA requirement for eccentric condensate formation. (A) Total RNA (in nanograms) of concentrated virion preparations. RNA concentration was
standardized by the p24 signal obtained from Western blots of multiple input volumes. Shown are averages (SD) from four independent experiments reported
as percentages of untreated HIV-Luc virions. (B) Average (SD) copies of vRNA per ng total RNA (n	 4) determined for the samples described for panel A. (C)
(Left) Core morphology frequencies in sets of 100 counted virions (average SD) from two independent isolates of particles prepared as described for panel A.
**, P 0.01; n.s., not significant (P	 0.37). (Right) Representative images of the mature, eccentric, dual electron density (ED), empty, and immature virions
observed in these experiments.
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IN virions transcomplemented with Vpr-INWT but not with
Vpr-INH171T. Concomitant with the gain in infectivity, the inci-
dence of conical cores rose from 9% to 30% upon Vpr-IN
transcomplementation (Fig. 10B). With Vpr-INWT, ALLINI treat-
ment restored this phenotype to the noncomplementedIN value
of 9%, whereas virions transcomplemented by Vpr-INH171T
harbored30% mature cores, regardless of ALLINI treatment.
DISCUSSION
In this study, we have utilized the recently discovered antiviral
activity of ALLINIs to assess the role of IN in HIV-1 maturation.
Of virions assembled in ALLINI-treated cells, the fraction that
acquires a closed conical capsid (taken to be a requirement for
infectivity [60]) is markedly reduced. Many of these capsids are
malformed. Moreover, in most of these virions, the vRNP is not
incorporated into the mature core but remains outside the capsid
as an “eccentric condensate,” even if a closed conical capsid is
assembled. These phenotypes are reproduced by various class II
IN mutations, including the V165A point mutation or IN dele-
tion. IN supplied in trans partially rescued the fraction of IN
virions that harbored WT cores with internal electron density, a
recovery that could be abolished by ALLINI treatment. As vRNA
was required for ALLINI-induced eccentric condensate forma-
tion, we suggest a model wherein disruption of an IN-vRNA in-
teraction, either by genetic or pharmacological means, results in
the inability to properly incorporate the vRNP into the capsid
during HIV-1 core morphogenesis.
ALLINI antiviral activity is due to inhibition of HIV-1 parti-
cle maturation. ALLINIs have been shown to inhibit several steps
of the HIV-1 replication cycle (see the introduction). However, it
has been unclear whether the inhibition of multiple steps com-
bines to determine drug potency or whether ALLINIs inhibit a
single bottleneck step in the replication cycle. To address this is-
sue, we correlated dose-response curves from inhibiting matura-
tion and reverse transcription, the first two steps that are inhibited
from the perspective of the drug-treated virus-producing cells, to
overall antiviral activity. As all three curves (percentage of mature
cores, reverse transcription activity, infectivity) effectively super-
posed with highly significant correlations for two representative
inhibitors, we conclude that inhibition of HIV-1 maturation de-
termines the antiviral potency of these compounds.
Similar to PIs (61), ALLINIs display relatively steep dose-re-
sponse curves (11, 18). Two mutually nonexclusive models for
this behavior posit that such compounds inhibit multiple copies
of the drug target at the relevant step of the replication cycle (61)
or that they inhibit multiple steps in the replication cycle (62).
Whereas inhibition of multiple replication steps appears to under-
lie the cooperative behavior of PIs (62), we conclude from our
data that ALLINIs mainly if not exclusively target IN during
HIV-1 maturation and, by inference, that multiple copies of IN, if
not the full virion complement of the protein, are affected. We
accordingly note similar slopes (m) of BI-D dose-response curves
for stimulation of purified IN multimerization in vitro (m, 2)
and inhibition of HIV-1 replication (m,2.8) (18).
Tomo-bubblegram imaging labels NC-containing com-
plexes in 3D. Cryo-ET and tomo-bubblegram imaging have given
a clearer account of the substructure of HIV-1 virions whose mat-
uration was subverted by a class II mutation in IN or by ALLINI
treatment. First, we confirmed earlier TEM data (12, 15, 18, 21)
that ALLINI treatment yields a high proportion of virions with
eccentric condensates. This property recurs in the class II IN mu-
tant control virus. Second, being able to visualize the 3D struc-
tures of complete virions in greater detail, we additionally found
an adverse effect of the V165A mutation and ALLINIs on capsid
morphogenesis.
We now consider the density inside conical capsids of mature
WT virions. This density has been interpreted as the vRNP, com-
posed primarily of NC and vRNA. The vRNP also contains the RT
and IN enzymes and some other viral and host cell components
(63–66). Serendipitously, NC turned out to be highly susceptible
to irradiation-induced bubbling, and we exploited this property to
FIG 10 IN in trans stimulates WT core formation in IN virions. (A) Infec-
tivity of HIV-Luc.IN transcomplemented with Vpr-INWT or Vpr-INH171T
made in the presence of BI-D or DMSO. Values were normalized to control
HIV-Luc virus constructed in the presence of DMSO. (B) (Upper) Quantita-
tion of core morphology frequencies of 100 counted virions (the IN muta-
tion yields more immature particles than does other class II [e.g., missense]
mutations [18, 46]). Shown are averages  SD for two independent experi-
ments for the transcomplemented preparations described for panel A. (Lower)
Representative images of the mature, eccentric, and immature virions ob-
served within experiments.
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demonstrate that NC is indeed a major internal component of WT
cores; moreover, the NC is primarily at the wide end of the core
(Fig. 5A to F; see also Movie S1 in the supplemental material and
reference 67). Because few bubbles are seen elsewhere in virions, it
seems that most if not all of the NC protein goes into the core.
These data directly support earlier evidence that most or all of NC
is in the core, whereby the ratio of NC to CA was found to be
significantly higher in isolated cores than in virions (68), in keep-
ing with the property that only about half of the CA present in an
immature virion assembles into a mature capsid (48, 49). Simi-
larly, our tomo-bubblegrams have shown that eccentric conden-
sates are rich in NC, with few bubbles seen anywhere else in con-
densate-containing virions.
The typical dimensions of the material enclosed in the wide
end of a WT core are similar to those of an eccentric condensate. It
appears therefore that when NC and the attached genomes are
released from the Gag shell in a maturing virion, they condense
into one or the other of these aggregates. A heuristic calculation
supports this inference. If one takes an eccentric condensate to
have major axes of 55 by 55 by 35 nm (see above), its volume is
55,000 nm3. Assuming50% of this volume to be occupied by
protein (a value typical for a protein crystal) and a protein density
of 0.78 kDa/nm3, a mass of 21.5 MDa results. Alternatively, an NC
copy number of2,000 to 2,500 per virion (1) and a subunit mass
of 7.2 kDa give a total mass of 14 to 18 MDa. Therefore, the
eccentric condensates are large enough to account for all of the NC
plus the two copies of the vRNA genome, which remain associated
with NC after virion maturation (64, 69).
Our analysis also shows that 12% of WT virions contain
eccentric condensate: of these, 75% have conical cores and 25%
have nonconical cores. An example is shown in Fig. 4B. The exis-
tence of such particles demonstrates miscarried vRNP incorpora-
tion into mature cores under the otherwise unperturbed WT sit-
uation of HIV-1 clade B strain NL4-3 assembly from transfected
HEK293T cells. Additional work with other viral clades and cell
types would be needed to discern how broadly applicable this
observation may be.
Implications for core assembly. In order to assemble a core,
Gag and Gag-Pol must be dissected by PR, with their component
domains being separated in a tightly regulated cleavage program
(70). Finally, CA is released from the maturing Gag shell into a
soluble pool, from where it assembles to form the mature core,
leaving about 50% unassembled (4, 26, 48, 49). During core as-
sembly, NC together with the vRNA and IN and RT enzymes
becomes situated into the mature core (see above).
Several models have been proposed for how capsid assembly
FIG 11 Model for the role of IN in coordinating HIV-1 capsid assembly and vRNP incorporation into the mature core. Maturation starts with activation of the
PR and dissection of the Gag and Gag-Pol polyproteins and release of the vRNP or NC from the Gag shell. The key element of this model is that it envisages a
molecular complex containing one or several copies of Gag-Pol that initiates both assembly of the capsid by an outgrowth of CA subunits and packaging of the
vRNA through binding to IN or to RT as conformationally influenced by IN. Many details remain to be clarified, including, for instance, whether other
components are involved in the putative complex, whether the initiation process starts with uncleaved Gag-Pol or whether the polyproteins have been
proteolytically processed, with the cleavage products remaining together, and whether capsid assembly begins at the wide or narrow end. We favor the wide end
because this narrows down to give a capsid of about the right length, which CA has been shown to be capable of in the absence of a membrane (71). The cartoon
shows RT and IN associated with the eccentric condensate for which there is currently no evidence, although they do remain, mostly or totally, inside the
wild-type capsid (66). A variant of this model in the Rous sarcoma virus system envisages participation of the cytoplasmic domain of Env (72). The virion and
core also contain other components (e.g., Vpr in the core and some host proteins somewhere in the virion), which are not shown.
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takes place (3, 4). They differ on whether assembly starts at the
wide end (3) or the narrow end (4) and are couched primarily in
terms of self-assembly properties attributed to CA protein, since
conical capsids similar to the ones observed inside HIV-1 virions
can be assembled from purified components in vitro (71). It has
also been suggested that the vRNP may help to nucleate assembly
(3, 5, 67), ensuring its incorporation into the capsid, and that MA
or the inner surface of the viral membrane could direct the closure
of the core (4). A related idea for coupling capsid assembly with
vRNA packaging was advanced for Rous sarcoma virus in that
some unprocessed or incompletely processed copies of Gag in the
Gag shell may form a nucleation complex that binds via the NC
moieties to a genomic packaging site and, via the CA moieties,
nucleates outgrowth of the capsid shell (72). Although IN has been
implicated in regulating PR activity during HIV-1 assembly and
particle release (59), a role for the viral enzyme in core morpho-
genesis has not been proposed. Based on our data, we propose an
active role for IN in initiating vRNP incorporation into the mature
core, which then nucleates capsid formation around the enclosed
vRNA-NC complex (Fig. 11). This scenario could in theory apply
to precleavage IN as a domain of Gag-Pol or postcleavage IN that
has remained in essentially the same position. Supporting a model
for an IN-vRNA interaction(s) in core morphogenesis, our data
reveal a role for vRNA in ALLINI-induced eccentric condensate
formation (Fig. 9) and high-affinity binding of purified HIV-1 IN
to RNA has been observed in vitro (73). A linkage between IN and
CA changes has, moreover, been noted among strains in drug-
naive and drug-experienced AIDS patients (74), indicating a po-
tential biological role for an IN-CA interaction. IN-RNA and
IN-CA interactions are two avenues that we are currently pursu-
ing to investigate the mechanistic basis of IN in HIV-1 core for-
mation and vRNP incorporation into the mature core.
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